跳至主要内容
临床试验/IRCT20200621047859N1
IRCT20200621047859N1招募中1 期

Phase I/II Clinical Trial using ex-vivo Expanded Haploidentical Donor-derived NK Cells against metastatic and refractory Breast cancer patients

Motamed Cancer Institute0 个研究点目标入组 30 人开始时间: 待定最近更新:
适应症

试验速览

阶段
1 期
状态
招募中
发起方
入组人数
30

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 65 years(—)
性别
Female

入选标准

  • Breast cancer diagnosed with pathological report
  • Approved according to Recist form for metastatic breast cancer
  • [EF=50%]EJECTION FRACTION
  • ElectroCochleoGraphy (ECoG) =0-1
  • ANC=1500, PH=100,000, GFR=60, T.Bil=1.5xULN, AST, ALT=2xULN
  • bHCG=negative
  • Ability to fill out a consent form and agree to its terms

排除标准

  • Receiving any anticancer drug at the same time
  • Major surgery one month before enrollment
  • An active infection that impairs a patient's tolerance for treatment
  • Breastfeeding or pregnancy

研究者

发起方
Motamed Cancer Institute

相似试验